KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Return on Capital Employed (2019 - 2026)

Moderna (MRNA) has disclosed Return on Capital Employed for 8 consecutive years, with 0.36% as the latest value for Q1 2026.

  • For Q1 2026, Return on Capital Employed fell 4.0% year-over-year to 0.36%; the TTM value through Mar 2026 reached 0.36%, down 4.0%, while the annual FY2025 figure was 0.27%, 1.0% up from the prior year.
  • Return on Capital Employed hit 0.36% in Q1 2026 for Moderna, down from 0.3% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.96% in Q1 2022 and bottomed at 0.36% in Q1 2026.
  • Average Return on Capital Employed over 5 years is 0.01%, with a median of 0.27% recorded in 2023.
  • Year-over-year, Return on Capital Employed surged 56bps in 2022 and then tumbled -85bps in 2023.
  • Moderna's Return on Capital Employed stood at 0.45% in 2022, then plummeted by -159bps to 0.27% in 2023, then decreased by -16bps to 0.31% in 2024, then grew by 3bps to 0.3% in 2025, then decreased by -20bps to 0.36% in 2026.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.36%, 0.3%, and 0.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.